Les anesthésiques généraux ne sont pas associés à un risque tératogène particulier. En raison de leur effet central, la plupart de ces agents peuvent entraîner une dépression respiratoire chez l’enfant lors d’une utilisation peu avant la naissance. Un risque augmenté d’hémorragie du post-partum a été décrit après une anesthésie générale, probablement en raison de l’effet relaxant sur le muscle utérin de la plupart des anesthésiques généraux. 1 Toute intervention chirurgicale est associée à un risque pour la mère et l’enfant à naître.
1. Heesen M , Hofmann T , Klohr S , et al. Is general anaesthesia for caesarean section associated with postpartum haemorrhage? Systematic review and meta-analysis . Acta Anaesthesiol Scand. 2013;57:1092-102.
2. Centre de référence sur les agents tératogènes de Paris. (Accessed at www.lecrat.org.)
3. Briggs GG , Freeman RK , Yaffe SJ. Drugs in pregnancy and lactation : A reference guide to fetal and neonatal risk. 9th ed. Lippincott Williams & Wilkins (LWW). 2011.
4. Schaefer C , Spielmann H , Vetter K , Weber-Schöndorfer C. Arzneimittel in Schwangerschaft und Stillzeit. 8 ed. Urban & Fischer Verlag/Elsevier GmbH. 2012.
5. Jonville-Béra AP , Vial T. Médicaments et grossesse : prescrire et évaluer le risque. Elsevier Masson. 2012.
6. Drugs and lactation database, Lactmed.
7. Hale TW. Medications and mothers’ milk. 14 ed. Hale Publishing. 2010.
8. Jurgens TP , Schaefer C , May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia. 2009;29:391–400.
9. Reynolds F. The effects of maternal labour analgesia on the fetus. Best Pract Res Clin Obstet Gynaecol. 2010;24:289–302.
10. Li DK , Liu L , Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage : Population based cohort study. BMJ. 2003;327:368.
11. Nielsen GL , Sorensen HT , Larsen H , Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs : Population based observational study and case-control study. BMJ. 2001;322:266–70.
12. Berard A , Kori S. Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache. 2012;52:1085–93.
13. Kallen B , Nilsson E , Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine : A register study in Sweden. Drug Saf. 2011;34:691–703.
14. Panchaud A , Weisskopf E , Winterfeld U , et al. Pharmacokinetic alterations in pregnancy and use of therapeutic drug monitoring. Therapie. 2014;69:223–34.
15. Tomson T , Battino D , Bonizzoni E , et al. Dose-dependent risk of malformations with antiepileptic drugs : An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609–17.
16. Habermann F , Fritzsche J , Fuhlbruck F , et al. Atypical antipsychotic drugs and pregnancy outcome : A prospective, cohort study. J Clin Psychopharmacol. 2013;33:453–62.
17. Reis M , Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy : An update using Swedish data. Psychol Med. 2010;40:1723–33.
18. Grigoriadis S , VonderPorten EH , Mamisashvili L , et al. Antidepressant exposure during pregnancy and congenital malformations : Is there an association ? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293–308.
19. Coleman T , Chamberlain C , Cooper S , Leonardi-Bee J. Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy : Systematic review and meta-analysis. Addiction. 2011;106:52–61.
